Many of the nonconfidential advances in our premier research and development pipeline, as well as data from investigator-initiated studies showing the benefits of our marketed drug OMIDRIA in “real-world” settings, are shared through an extensive list of peer-reviewed publications and posters presented at international conferences.
Medical and Scientific Publications
OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% /
0.3% Publications:
2019
Reduction in surgical time and iris manipulation using a continuous intracameral irrigation of phenylephrine and ketorolac for miosis prevention in femtosecond laser-assisted cataract surgery.
Walter K, Delwadia N, Cohen J. J Cataract Refract Surg. Published online ahead of print January 17, 2019. doi:10.1016/j.jcrs.2018.11.004.
2018
Medical and surgical management of the small pupil during cataract surgery.
Al-Hashimi S, Donaldson K, Davidson R, et al; ASCRS Refractive Cataract Surgery Subcommittee. J Cataract Refract Surg. 2018;44:1032-1041.
Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery.
Rosenberg ED, Nattis AS, Alevi D, et al. Clin Ophthalmology. 2018;12:21-28.
Effect of phenylephrine 1.0%-ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome.
Silverstein SM, Rana VK, Stephens R, et al. J Cataract Refract Surg. 2018;44(9):1103-1108.
Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis.
Visco D. Clin Ophthalmology. 2018;12:301-305.
Alternative drug delivery for patients undergoing cataract surgery as demonstrated in a canine model.
Waterbury LD. J Ocul Pharmacol Ther. 2018;34:154-160.
2017
Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery.
Bucci FA, Michalek B, Fluet AT. Clin Ophthalmology. 2017;11:1039-1043.
Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery.
Donnenfeld ED, Whitaker JS, Jackson MA, Wittpenn J. J Cataract Refract Surg. 2017;43:597-605.
Intracameral ketorolac concentration at the beginning and end of cataract surgery following preoperative topical ketorolac administration.
Katsev DA, Katsev CC, Pinnow J, Lockhart CM. Clin Ophthalmology. 2017;11:1897-1901.
Importance of pupil dilation for cataract surgery.
Mamalis N. J Cataract Refract Surg. 2017;43(5):583-584.
2016
Patient considerations in cataract surgery – the role of combined therapy using phenylephrine and ketorolac.
Gonzalez-Salinas R, Guarnieri A, Guirao Navarro MC, Saenz-de-Viteri M. Patient Prefer Adherence. 2016;10:1795-1801.
2015
Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: Integrated results from 2 pivotal phase 3 studies.
Hovanesian JA, Sheppard JD, Trattler WB, et al. J Cataract Refract Surg. 2015;41:2060-2068.
The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery.
Lawuyi LE, Gurbaxani A. Clin Ophthalmology. 2015;9:1249-1254.
OMS302 (phenylephrine and ketorolac injection) 1%/0.3% to maintain intraoperative pupil size and to prevent postoperative ocular pain in cataract surgery with intraocular lens replacement.
Osher RH, Ahmed IIK, Demopulos GA. Expert Rev Ophthalmol. 2015;10(2):91-103.
2014
Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions.
Grob SR, Gonzalez-Gonzalez LA, Daly MK. Clin Ophthalmology. 2014;8:1281-1289.
Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification.
Lindstrom RL, Loden JC, Walters TR, et al. Clin Ophthalmology. 2014;8:1735-1744.
Narsoplimab (OMS721) Publications:
2019
Interim results from an ongoing phase 2 study evaluating the use of a MASP-2 inhibitor for the treatment of IgA nephropathy.
Barratt J, Leifke E, Whitaker S, et al. Presented at: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). June 13-16, 2019. Budapest, HU. Poster FP201.
2018
Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction.
Clark JE, Dudler T, Marber MS, Schwaeble W. Open Heart. 2018;5(1):e000652. doi:10.1136/openhrt-2017-000652.
Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA).
Rambaldi A, Khaled S, Smith M, et al. Presented at: European Hematology Association (EHA); June 15, 2018; Stockholm, Sweden.
2017
The effect of OMS721 on proteinuria in patients with IgA nephropathy.
Block G, Whitaker S. Presented at: European Renal Association—European Dialysis and Transplant Association (ERA-EDTA); June 4, 2017; Madrid, Spain.
Maintenance of remission following completion of OMS721 treatment in Patients with IgA nephropathy (IgAN).
Block G, Whitaker S. Presented at: American Society of Nephrology (ASN); November 6, 2017; New Orleans, LA.
Effective treatment of GvHD-associated transplant-associated microangiopathy.
Caprioli C, Grassi A, Micò C, Rambaldi A. Presented at: European Society for Blood and Marrow Transplantation (EBMT); October 19-20, 2017; Granada, Spain.
Early results of a phase 2 study using OMS721 in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA).
Khaled SK, Kwong YL, Smith M, Metjian A, Whitaker S. Presented at: American Society of Blood and Marrow Transplantation (ASBMT); February 25, 2017; Orlando, FL.
Dose-finding clinical trial of OMS721 for the treatment of atypical hemolytic uremic syndrome (aHUS) – stage 1 results.
Nowicki M, Wiecek A, Massart A, Weekers L, Whitaker S, Miglinas M. Presented at: World Congress of Nephrology (WCN); April 21-25, 2017; Mexico City, Mexico.
Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2.
Yaseen S, Demopulos G, Dudler T, et al. FASEB J. 2017;31(5):2210-2219. doi:10.1096/fj.201601306R.
Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient.
Zecca M, Comoli P, Mina T, Decembrino N, et al. Presented at: European Society for Blood and Marrow Transplantation (EBMT); March 26-29, 2017. Marseille, France.
2016
Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1.
Orsini F, Chrysanthou E, Dudler T, et al. J Neuroinflammation. 2016;13(1):213. doi:10.1186/s12974-016-0684-6.
2014
Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4.
2011
Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury.
2010
Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.
Other Publications:
PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission.
de Guglielmo G, Melis M, De Luca MA, et al. Neuropsychopharmacology. 2015;40(4):927-937. doi:10.1038/npp.2014.268.
Selection of targeted mutants from a library of randomly mutagenized ES cells.
Horie K, Gaitanaris G, Gragerov A. Methods Mol Biol. 2011;693:283-294. doi:10.1007/978-1-60761-974-1_17.
An inducible and reversible mouse genetic rescue system.
Zeng H, Horie K, Madisen L, et al. PLoS Genet. 2008;4(5):e1000069. doi:10.1371/journal.pgen.1000069.
Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding.
Zeng H, Gragerov A, Hohmann JG, et al. Mol Cell Biol. 2006;26(24):9352-9363.
